Vladimira B.
- Country
- Bulgaria
- Department
- NA
Research Overview
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Subcutaneous Ianalumab (VAY736) Added to Standard Therapy in Systemic Lupus Erythematosus
- Phase 3 Randomized Double-blind Placebo-controlled Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
- Phase 2 Randomized Double-Blind Placebo-Controlled Study of ELV001 Add-On Therapy in Patients With Active Rheumatoid Arthritis Inadequate to Methotrexate and TNF Inhibition
Data & Insights
Has run more than one trial at 149 of 352 partner sites.
Specializations
Autoimmune Disorders
The investigator specializes in treating complex systemic autoimmune conditions, with particular focus on Sjögren's disease and Systemic Lupus Erythematosus. Their research extends to innovative therapeutic approaches for managing these chronic conditions.
- Sjögren's Disease Management
- Lupus Treatment Protocols
- Systemic Sclerosis Care
Their work involves evaluating novel therapeutic agents for autoimmune disease management.
Inflammatory Conditions
The investigator focuses on treating various inflammatory disorders, including dermatomyositis and psoriatic arthritis. Their expertise encompasses both rare and common inflammatory conditions.
- Polymyositis Treatment
- Psoriatic Arthritis Management
- Inflammatory Myopathies
Their research addresses the complex nature of inflammatory diseases and their systemic manifestations.
Immune-Mediated Disorders
The investigator specializes in treating various immune-mediated conditions, including immune thrombocytopenia, Behçet's Syndrome, and bullous pemphigoid.
- Antiphospholipid Syndrome
- Immune-Mediated Necrotizing Myopathy
- Complement Pathway Disorders
Their work involves exploring novel therapeutic approaches for rare immune disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.